Current consensus and controversy in neoadjuvant therapy for pancreatic cancer
10.3760/cma.j.issn.0529-5815.2020.02.005
- VernacularTitle: 胰腺癌新辅助治疗的共识及争议
- Author:
Zhenglin OU
1
;
Yixiong LI
1
;
Liandong JI
1
;
Mujing KE
2
Author Information
1. Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
2. Department of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha 410008, China
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Clinical protocols;
Neoadjuvant therapy;
Consensus;
Controversy
- From:
Chinese Journal of Surgery
2020;58(2):99-104
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is malignant and has a poor prognosis.At present, the treatment mode has changed from "Surgery First" to systemic therapy under multi-disciplinary team, but surgical resection is still the only way to cure pancreatic cancer. In systemic treatment of pancreatic cancer, the effect of postoperative adjuvant therapy is significant, and preoperative neoadjuvant therapy has gradually attracted widespread attention. Neoadjuvant therapy can improve the rate of R0 resection in patients with pancreatic cancer.There is a consensus on neoadjuvant therapy for patients who with borderline resectable and locally advanced, but for the patients who with resectable remains controversial.
